The third dose of the SARS-CoV-2 vaccine vaccinated the first vulnerable patients



[ad_1]

“In a study of the largest sample published to date in the world, we found that almost a fifth of patients with blood diseases do not develop immunity to the SARS-CoV-2 virus after two doses of the vaccine, and approximately half of our patients have lower immunity. We have also identified specific conditions and treatments that particularly reduce the response to vaccines “, the press release quoted the director of the Center for Hematology, Oncology and Transfusionology at Clinicas Santara, Prof. Laimonas Griškevičius .

“The first small-scale studies by researchers around the world suggest that a third dose of the vaccine can boost immunity. The third dose of the vaccine is already recommended by Israeli and French specialists for vulnerable groups.

Doctors at the Santara clinics plan to vaccinate patients with blood diseases, hemodialysis and patients after an organ transplant in the next month. Santara clinics have been applying the complex ‘zero COVID-19’ principles since spring: Only the most vulnerable groups of patients work with those with immunity to COVID-19, they are regularly tested using the combined PCR method developed by the Santara Clinic for SARS-CoV-2 Viruses, all conventional protections apply.

Ignas Meidus, a leukemia patient who has had leukemia for six years and has had a bone marrow transplant for six years, is optimistic. It says previous vaccines did not produce antibodies, possibly due to the need to take immunosuppressive medications. He is not currently using them, so both the doctors and Ignas expect good results after this third vaccination. Ignas, anyone who fears or doubts about vaccination, wants to trust the doctor more and be healthy.

It is strictly forbidden to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, it is necessary to cite DELFI as the source. .



[ad_2]